Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Novartis to divest blood transfusion diagnostics unit to Grifols, may sell animal health and OTC units
2:37 AM MST | November 11, 2013 | Natasha Alperowicz
Pharmaceuticals major Novartis (Basel) today announced a definitive agreement to divest its blood transfusion diagnostics unit, headquartered in Emeryville, CA, to Grifols (Barcelona) for $1.675 billion. This transaction, requiring customary regulatory approvals, is expected to be completed in the first half of 2014. "The sale of the Novartis blood transfusion diagnostics unit enables us to focus more sharply on our strategic businesses while providing Grifols with a platform for global expansion," said Joseph Jimenez CEO of Novartis. "I am...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee